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(2), RVF post cardiac surgery (1), RVF post LVAD implantation (2) and RVF post acute
myocardial infarction (1). All patients were in cardiogenic shock prior to Impella RP
implant.The percutaneous implant of the device was feasible and successful in 100% of the
patients. The support time ranged from 1 to 9 days, with more than 60% of the patients being
supported for longer than 4 days (median of 6.5 days) and explanted upon RV recovery. The
average flow was 3.9 L/min. Overall thirty-day survival was 83%.
Conclusions: A novel percutaneous right ventricular assist device has been developed.
The design was enhanced after the first implant to improve torque-ability and push-ability
which resulted in an ease of placement for the subsequent patients. The preliminary
clinical experience is very encouraging and further evaluation is ongoing.
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Coronary artery disease in patients with reduced left ventricular systolic
function treated with medicine, surgery, or percutaneous coronary
intervention: a retrospective review of outcomes within a multicenter
healthcare system
Matthew LaBarbera1, Peter Hui1, Richard Shaw1
1California Pacific Medical Center, San Francisco, CA
Background: Patients with multivessel coronary artery disease (CAD) and
reduced left ventricular ejection fraction (LVEF) are at risk for significant
morbidity and mortality. There is limited data comparing medical therapy,
coronary artery bypass graft surgery (CABG), and percutaneous coronary inter-
vention (PCI) in patients with CAD and LVEF 35%. The current study evaluates
the clinical characteristics and outcomes for patients with significant CAD and
reduced LVEF treated with medical therapy, CABG, or PCI.
Methods: A retrospective analysis was conducted on consecutive patients in the Sutter
Health System in Northern California without prior CABG who underwent coronary
angiography between 1/1/2003 and 12/31/2009 and were found to have LVEF35% and
significant CAD (left main stenosis 50% or greater, proximal LAD stenosis 70% or
greater, or 70% stenosis in 2 or more major epicardial vessels). Patients undergoing
emergent cardiac catheterization were excluded. A Cox proportional hazards regression
analysis was performed to compare medical therapy, CABG, and PCI for the outcome of
long-term survival, adjusting for baseline demographic and clinical characteristics. The
Social Security death index was used to assess long-term mortality.
Results: 1345 patients with CAD and reduced LVEF were identified: 498 had PCI, 493
had CABG, and 354 received medical therapy alone. Patients receiving medical therapy
alone were more likely to be female, have a history of myocardial infarction, and have a
history of heart failure (p0.001). In-hospital mortality rates for the CABG, PCI, and
medical therapy groups were similar (6.7% vs. 5.4% vs. 9.0 %; p0.118). The 5-year
adjusted survival for the CABG, PCI, and medical therapy cohorts was 76%, 65%, and
52%, respectively (p0.0001).
Conclusions: In a large hospital network, patients with CAD and reduced LVEF had
improved long-term mortality when treated with revascularization (CABG or PCI) compared
with medical therapy alone. Notably, patients with CAD and reduced LVEF had improved
long-term mortality when treated with PCI compared with medical therapy. Further studies are
warranted regarding the optimal treatment for patients with CAD and reduced LVEF.
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Impact of Epicardial Fat Volume on Coronary Artery Disease in Symptomatic
Patients with a Zero Calcium Score
Tsuyoshi Ito1, Mitsuyasu Terashima1, Kenya Nasu1, Masashi Kimura1,
Yoshihisa Kinoshita1, Yasushi Asakura1, Etsuo Tsuchikane1, Takahiko Suzuki1
1Toyohashi Heart Center, Toyohashi, Japan
Background: Prevalence of coronary artery disease (CAD) is not fully elucidated in
symptomatic patients with a zero calcium score (CS) by computed tomography (CT).
Epicardial fat volume (EFV) has been suggested as a predictor of CAD. The aim of our
study is to investigate the prevalance of CAD and the impact of EFV on CAD in
symptomatic patients with a zero CS with multislice CT (MSCT).
Methods: In this study, 1308 consecutive symptomatic patients who underwent 64-slice
MSCT with a zero CS were evaluated. EFV was quantified with CS data sets. Presence
of an obstructive plaque (diameter stenosis50%) and a CT-derived vulnerable plaque,
which was defined as a plaque with remodeling index1.10 and mean CT density value
30Hounsfield Units, was assessed with a CT coronary angiography.
Results: Obstructive plaques were detected in 86 patients (7%) and CT-derived
vulnerable plaques in 63 (5%). EFV was larger in patients with obstructive plaques than
no plaque (124.343.2cm3 vs. 95.140.3cm3; p0.01). Patients with CT-derived
vulnerable plaques had a greater amount of EFV than no plaque (133.040.2cm3 vs.
95.140.3cm3; p0.01). Multivariate analysis revealed EFV as a predictor of the
presence of an obstructive and a CT-derived vulnerable plaque (per 10cm3; Odds ratio
(OR) 1.10; 95% confidence interval (CI), 1.04-1.16; p0.01 and OR 1.19; 95% CI,
1.12-1.27; p0.01). The combination of EFV and Framingham risk score (FRS) resulted
in an area under the receiver-operating characteristic curve for prediction of obstructive
and CT-derived vulnerable plaque of 0.75 and 0.75, which was significantly higher than
0.68 and 0.64 for FRS alone (p 0.02 and p0.01).
Conclusions: A zero CS doesn’t exclude CAD and EFV can be a useful marker of CAD
in symptomatic zero CS patients.
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Long-term Survival and Neurological Outcome of In-hospital Cardiac Arrest
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Background: The immediate clinical benefit of extracorporeal cardiopulmonary resus-
citation (E-CPR) has been proved in short-term follow-up studies. However, it has been
not known whether the benefit of E-CPR persists for more than 1 year. We compared the
long-term outcomes of patients who received E-CPR or conventional CPR (C-CPR) and
investigated the clinical characteristics of long-term survivors.
Methods: We analyzed a total of 406 adult in-hospital cardiac arrest victims received
CPR for more than 10 minutes from 2003 to 2009. The long-term survival and
neurological outcome of E-CPR (n85) and C-CPR (n321) were compared using
propensity score-matched analysis.
Results: The 2-year survival with minimal neurological impairment was 4-fold higher in
E-CPR group than C-CPR group (23.5% versus 5.9%, hazard ratio (HR)  0.57, 95%
confidence interval (CI)  0.43–0.75, p0.001) by unadjusted analysis. After propensity-
score matching, it was still 4-fold higher in E-CPR group than C-CPR group (20.0% versus
5.0%, HR0.53, 95% CI0.36–0.80, p0.002). In the E-CPR group, the independent
predictors associated with minimal neurological impairment were age65 years (HR0.46;
95% CI0.26–0.81; p0.008), CPR duration 35 min (HR0.37; 95% CI0.18–0.76;
p0.007), and subsequent cardiovascular intervention including coronary intervention or
cardiac surgery (HR0.36; 95% CI0.18–0.68; p0.002).
Conclusions: The initial survival benefit of E-CPR for cardiac arrest patients was
maintained at 2 year.
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Optimizing Rotational Atherectomy in High-Risk Percutaneous Coronary
Interventions. Insights from the PROTECT  study
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Background: Rotational Atherectomy (RA) is currently recommended for heavily
calcified lesions in which standard percutaneous coronary intervention (PCI) techniques
would result in suboptimal stent expansion. We sought to determine the optimal RA use
associated with minimal incidence of myonecrosis in patients undergoing high-risk PCI
supported by either intraaortic balloon (IABP) or microaxial flow pumps (Impella).
Methods: We performed a subgroup analysis of patients treated with RA in the
PROTECT  trial. The objective was to examine the relationship between myonecrosis
and the technical parameters burr size, number of passes/patient/lesion, and RA time.
Peri-procedural myocardial infarction (MI) was defined in the study as increase of
CK-MB or Troponin 3xULN. Continuous variables were expressed as means SD. A
P value 0.05 was considered significant.
Results: RA was used in 52 patients of the 448 PROTECT II patients (11.6%).
Compared to patients treated without RA, patients undergoing RA were older (72
vs. 67 yo, p0.001), were more likely to have heart failure (96% vs. 86%,
p0.04), prior CABG (48 vs. 32%, p0.02), higher STS score (8.1 vs. 5.7,
p0.04), and higher Syntax score (40 vs. 29, p0.0001). Myonecrosis occurred
in 25% of RA cases. Of note, lesion length was similar in patients with and
without myonecrosis (39 vs. 38 mm, p0.96). Prolonged RA time was associated
with increased incidence of periprocedural myonecrosis (Table).
Variable MI (n12) No MI (n40) p value
Burr size (mm) 1.70.25 1.6 0.2 0.18
Number of passes/lesion 3.0 1.7 2.7 1.9 0.36
Number of passes/patient 6.4 3.6 4.7 3.8 0.15
RA time (seconds) 85.9 53.8 55.3 47.2 0.03
Conclusions: RA continues to be utilized in high-risk PCI procedures. Our study
suggests that longer RA time is associated with myonecrosis in patients undergoing
high-risk PCI. Optimal RA technique must balance the risk of myonecrosis against the
imperative to achieve a good luminal result.
TCT-376
SIMPLIPHieDE Study - Single center IMPella LVAD supported Pci in High Risk
group of patients – Detroit Medical Center Experience – Clinical Outcomes
Haroon Faraz1, Tamam Mohamad1, Rohit Amin1, Hassan Ismail1,
Obrad Kokanovic1, Antwon Robinson1, Sabeeh Siddiqui1, Muhammad Shahzad1,
Theodore Schreiber1
1Detroit Medical Center Cardiovascular Institute Wayne State University, Detroit, MI
Background: Advances in percutaneous interventional techniques and technology have
made percutaneous coronary intervention (PCI) for left main and or triple vessel disease
a viable option. Left main intervention was re-classified in the recent ACC guidelines
from III to IIb based on the large randomized Syntax trial. Though patients with high
syntax score still continue to benefit from CABG, in real-world clinical practice patients
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with left main and or triple vessel CAD often have significant co-morbidities making them
extremely high risk for mortality & morbidity related to post-CABG recovery. For such
patients Impella supported PCI is feasible.
Methods: Retrospective analysis of 225 procedures in 200 patients undergoing high risk
PCI with Impella assist between 8/2008 and 5/2012 from an inner city hospital with
multiple co-morbidities was evaluated in this study. We present their demographics,
in-hospital and 30 day survival along with co-morbidities (STS, EUROSCORE I & II and
PARSONNET) and coronary risk profile based on Syntax scoring.
Patient Characteristics
Age (mean) 78.4 years	/ 8.3
Caucasians/African-americans 55%/42%
Gender % ( males/females ) 73.5/26.5
LVEF (mean) 24%	/ 12%
Co-morbidities
Prior MI 72%
Prior PCI 69%
Diabetes (on medications oral/insulin) 67%
PVD 44%
CKD Stage IV/V (GFR  30) 36%
COPD ( on inhalers ) 32%
Prior CABG 28%
Co-morbidity based mortality Risk Scoring
STS – Mean Risk of Procedural Mortality 6.3%	/ 4.8 %
STS – mean Mortality or morbidity 36.8%	/ 13.7%
Mean EuroSCORE II predicted mortality 16.67%	/ 9.8%
Mean EUROSCORE predicted mortality(logistic) 40.5%	/ 18%
Mean Parsonnet predicted 30 day mortality 20.5%	/ 10.3%
Coronary Lesion Characteristics and Syntax risk scoring
Left Main 	 multivessel 43%
Multivessel 34%
Syntax Scoring 0-22 52%
Syntax Score 23-32 38%
Syntax Score  33 10%
Results: Among the 200 patients who underwent 225 high-risk PCI with Impella support,
there was only 1/225 (0.44 %) in-hospital mortality. The mean length of hospital stay was
3.71 	/ 1.9 days. 2 patients were lost to follow up, of the remaining 197 patients, the
30 day survival was 99.5%.
Conclusions: Our experience demonstrates that use of the Impella 2.5 for prophylactic
circulatory support during high-risk PCI in the “real world” is safe and feasible, expanding
treatable patient populations. The excellent outcomes rival or exceed those for published
contemporary CABG series for low, intermediate or high risk patients.
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Impact of New-Onset Acute Heart Failure in Patients with Acute Myocardial
infarction Underwent Successful Revascularization
Keun-Ho Park1, Myung Ho Jeong1, Youngkeun Ahn1, Jong Hyun Yoo1,
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Background: There are a few data of clinical outcome of new-onset acute heart failure
(AHF) during hospitalization in patients with acute myocardial infarction (AMI) under-
went successful revascularization.
Methods: We analyzed 7,064 AMI patients with Killip class I at admission underwent
successful percutaneous coronary intervention from Korea Acute Myocardial Infarction
Registry between Oct. 2005 and Jan. 2008. Of these, 120 patients (1.7%) suffered from
new-onset AHF during their hospitalization.
Results: Patients with AHF were older and more common in female gender and ST
elevation MI than those without AHF. Patients with AHF also were more likely to have
low left ventricular ejection fraction (LVEF) and low creatinine clearance than those
without AHF. Multi-vessel disease or left main disease and complex target lesion and
incomplete revascularization were more frequently in patients with AHF than those
without AHF (p0.005 respectively). Patients with AHF had significantly higher
incidence of in-hospital mortality and l-year mortality than those without AHF (23.3% vs.
0.5%; 38.2% vs. 2.9%, p0.001 respectively). Multiple regression analysis demonstrated
that new-onset AHF [Odds ratio (OR)18.533; 95% Confidence interval (CI)7.505-
45.764], ventricular tachycardia/fibrillation (OR8.826; 95% CI3.123-24.949), LVEF
50% (OR4.092; 95% CI1.741-9.620) and age (OR1.058; 95% CI1.013-1.106)
were independent predictors for in-hospital mortality in AMI patients. The independent
predictors of development of new-onset AHF in patient with AMI underwent successful
revascularization were ventricular tachycardia/fibrillation (OR10.567; 95% CI6.089-
18.336), LVEF 50% (OR2.037; 95% CI1.298-3.197), ST elevation MI
(OR2.522; 95% CI1.369-4.646), SBP 120mmHg (OR1.839; 95% CI1.186-
2.852) and Atrioventricular block (OR3.062; 95% CI1.276-7.177).
Conclusions: New-onset AHF rarely occurred in patients with AMI underwent
successful revascularization, however, was highly associated with in-hospital
mortality. Therefore, even though they underwent successful revascularization,
intensive treatment and careful monitoring should be required for patients with
high risk of new-onset AHF.
TCT-378
Interim analysis of the Reitan Catheter Pump (RCP) heart failure efficacy
study: RCP improves cardiovascular and renal function in acute
decompensated heart failure (ADHF)
Thomas Keeble1, Elliot Smith1, Markus Ferrari2, Roger Hullin3,
Scherstén Fredrik4, Oyvind Reitan4, Martin Rothman5
1London Chest Hospital, London, London, 2University Heart Center Jena, Jena,
Germany, 3CHUV, Lausanne, Vaud, 4University Hospital, Lund, Getingevägen 4,
5The London Chest Hospital, London, United Kingdom
Background: The RCP is a 14 French collapsible percutaneous cardiovascular support
device positioned in the descending part of the thoracic aorta via the femoral artery. A 10
patient first in man study demonstrated device safety and significant improvement in renal
function among high risk PCI patients. We now report haemodynamic and renal efficacy
in patients with ADHF.
Methods: Prospective non randomised multi-centre study seeking to recruit 20 patients
with ADHF with a need for inotropic or mechanical circulatory support with: i) EF 
30% ii) Cardiac index(CI) 2.2 L/min/m2 Outcome measures included: 1) Cardiac index
(CI) 2) Pulmonary Capillary Wedge Pressure (PCWP) 3) Urine output/serum creatinine/
eGFR 4) Vascular/device complications 5) 30 day mortality.
Results: INTERIM ANALYSIS (n14) The mean age of the study group was 64.5
years.The intended RCP treatment period was 24 hours. During RCP treatment there was
a 30% improvement in mean Cardiac Index (CI) measured at 24 hours (1.85 to 2.45
L/min/m2 p0.08), and a concomitant trend towards reduction in PCWP at 24 hours of
26% (27 to 20 mmHg p0.28). RCP insertion prompted substantial diuresis. Urine output
doubled over the first 24 hours compared to baseline (74 ml/hr vs 157 ml/hr p0.006).
This was associated with significantly improved renal function, a 22% reduction in serum
creatinine at 24 hours (174 to 142 umol/L p0.0002), and a increase in eGFR from 50.2
ml/min to 61 ml/min (p0.001). 2 patients previously refused cardiac transplantation
were reassessed and successfully transplanted within 9 months of RCP treatment on the
basis of demonstrable renal reversibility. There were no vascular or device complications.
There were 2 deaths at 30 days, one from multi-organ failure and sepsis, and one from
intractable heart failure - neither were device related.
Conclusions: The Reitan Catheter Pump improves haemodynamics and renal function in
the acutely decompensated cardiac patient, and may have a role in suggesting renal
reversibility in potential cardiac transplant patients. Further data will be reported at
recruitment completion.
TCT-379
Percutaneous Transcatheter Aortic Valve Closure Successfully Treats Left
Ventricular Assist Device-Associated Aortic Insufficiency and Improves
Cardiac Hemodynamics
Kishan Parikh1, Amit Mehrotra1, Mark Russo1, Roberto Lang1, Allen Anderson1,
Valluvan Jeevanandam1, Benjamin Freed1, Jonathan Paul1, Janet Karol1,
Sandeep Nathan1, Atman Shah1
1University of Chicago, Chicago, IL
Background: The increased use of continuous-flow LVADs in advanced heart failure
has led to marked changes in the management of patients with this condition. However,
secondary AI can become a significant complication. Our objective was to assess the
effectiveness of a novel percutaneous method to treat left ventricular assist device
(LVAD)-associated severe aortic insufficiency (AI) in a series of patients determined to be
poor reoperative candidates.
Methods: Five patients with continuous-flow LVADs and severe post-LVAD AI
underwent percutaneous transcatheter aortic valve (AV) closure with the Amplatzer™
Cribiform device (AGA Medical, Plymouth, MN) between September to October 2011 at
a single quaternary care academic medical center. All patients had LVADs implanted as
destination therapy. LVAD parameters, hemodynamics, and echocardiographic measure-
ments were obtained before and after AV closure.
Results: All patients underwent successful closure with the Amplatzer™ Cribiform
device via a percutaneous transcatheter femoral approach with a significant reduction of
AI from severe to trivial (p0.05). Cardiac hemodynamics improved and the pulmonary
capillary wedge pressure (PCWP) was reduced in all patients (p0.05). There was no
change in mitral or tricuspid regurgitation, LVAD power or pulsatility index.
Conclusions: Percutaneous transcatheter closure of the aortic valve effectively treats
LVAD-associated AI and reduces PCWP. This procedure should be considered to treat
LVAD-associated AI in patients who are poor candidates for repeat operation. Further
data is needed to assess long-term results.
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